This titrate-up and taper-down controversy stems from concerns regarding the potential for hyperglycemia upon initiation of total parenteral nutrition (TPN) and for hypoglycemia upon discontinuation.
ENGLEWOOD, Colo., April 7 /PRNewswire/ -- Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations and increase patient safety, today announced the release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback